Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Pipeline Review, H2 2018
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Pipeline Review, H2 2018
SUMMARY
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of actin cytoskeleton and cell polarity. It is involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. It phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. It acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. It acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation.
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) pipeline Target constitutes close to 16 molecules. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 11 and 2 respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Ophthalmology, Cardiovascular, Metabolic Disorders, Musculoskeletal Disorders, Non Malignant Disorders and Oncology which include indications Idiopathic Pulmonary Fibrosis, Glaucoma, Graft Versus Host Disease (GVHD), Kidney Fibrosis, Acute Spinal Cord Injury, Alzheimer's Disease, Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma), Chronic Kidney Disease (Chronic Renal Failure), Chronic Obstructive Pulmonary Disease (COPD), Diabetic Nephropathy, Fibrosis, Huntington Disease, Inflammation, Inflammatory Bowel Disease, Multiple Sclerosis, Neurodegenerative Diseases, Non-Alcoholic Steatohepatitis (NASH), Pain, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Solid Tumor, Stroke, Systemic Sclerosis (Scleroderma) and Traumatic Spinal Cord Injury.
The latest report Rho Associated Protein Kinase 2 - Pipeline Review, H2 2018, outlays comprehensive information on the Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of actin cytoskeleton and cell polarity. It is involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. It phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. It acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. It acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation.
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) pipeline Target constitutes close to 16 molecules. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 11 and 2 respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Ophthalmology, Cardiovascular, Metabolic Disorders, Musculoskeletal Disorders, Non Malignant Disorders and Oncology which include indications Idiopathic Pulmonary Fibrosis, Glaucoma, Graft Versus Host Disease (GVHD), Kidney Fibrosis, Acute Spinal Cord Injury, Alzheimer's Disease, Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma), Chronic Kidney Disease (Chronic Renal Failure), Chronic Obstructive Pulmonary Disease (COPD), Diabetic Nephropathy, Fibrosis, Huntington Disease, Inflammation, Inflammatory Bowel Disease, Multiple Sclerosis, Neurodegenerative Diseases, Non-Alcoholic Steatohepatitis (NASH), Pain, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Solid Tumor, Stroke, Systemic Sclerosis (Scleroderma) and Traumatic Spinal Cord Injury.
The latest report Rho Associated Protein Kinase 2 - Pipeline Review, H2 2018, outlays comprehensive information on the Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1)
- The report reviews Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Overview
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AbbVie Inc
Angion Biomedica Corp
Astex Pharmaceuticals Inc
BioAxone BioSciences Inc
HitGen LTD
Kadmon Corp LLC
Redx Pharma Plc
Vertex Pharmaceuticals Inc
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Drug Profiles
ANG-4201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-13148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-2017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-025 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KL-00148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KL-00974 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KL-01045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDX-8087 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology, Metabolic Disorders and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROCK2 for Fibrotic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ROCK1 and ROCK 2 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VX-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Dormant Products
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Discontinued Products
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Aug 08, 2018: BioAxone BioSciences receives notice of allowance on patent for treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
Jul 10, 2018: BioAxone BioSciences Receives Notice of Allowance for Composition of Matter Patent Covering Novel ROCK2 Inhibitor
Jun 15, 2018: Kadmon Announces Updated Results of KD025 in cGVHD at EHA Congress
May 17, 2018: Kadmon Announces Oral Presentation on KD025 in cGVHD at EHA Congress
Apr 10, 2018: Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host Disease
Feb 22, 2018: Kadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHD
Feb 12, 2018: Kadmon Announces Positive Top line Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis
Feb 12, 2018: Kadmon to Host Webcast and Conference Call to Discuss Topline Results of KD025 in IPF
Dec 10, 2017: Kadmon Presents Updated Positive Phase 2 Data on KD025 in cGVHD at ASH Annual Meeting
Nov 01, 2017: Kadmon to Present New Data from Ongoing Phase 2 Study of KD025 in cGVHD at ASH Annual Meeting
Oct 06, 2017: FDA Grants Orphan Drug Designation to Kadmon’s KD025 for the Treatment of cGVHD
Aug 11, 2017: Kadmon to Present Preclinical Data on ROCK Inhibition in Pulmonary Fibrosis at IPF Summit 2017
Aug 02, 2017: BioAxone BioSciences Receives Notice of Award for NIH/SBIR Funding of IND-Enabling Studies to Continue Development of BA-1049 to Treat Cerebral Cavernous Malformations
Jul 25, 2017: Kadmon Announces Supplemental Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
Jul 11, 2017: Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Overview
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AbbVie Inc
Angion Biomedica Corp
Astex Pharmaceuticals Inc
BioAxone BioSciences Inc
HitGen LTD
Kadmon Corp LLC
Redx Pharma Plc
Vertex Pharmaceuticals Inc
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Drug Profiles
ANG-4201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-13148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-2017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-025 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KL-00148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KL-00974 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KL-01045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDX-8087 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology, Metabolic Disorders and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROCK2 for Fibrotic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ROCK1 and ROCK 2 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VX-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Dormant Products
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Discontinued Products
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Aug 08, 2018: BioAxone BioSciences receives notice of allowance on patent for treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
Jul 10, 2018: BioAxone BioSciences Receives Notice of Allowance for Composition of Matter Patent Covering Novel ROCK2 Inhibitor
Jun 15, 2018: Kadmon Announces Updated Results of KD025 in cGVHD at EHA Congress
May 17, 2018: Kadmon Announces Oral Presentation on KD025 in cGVHD at EHA Congress
Apr 10, 2018: Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host Disease
Feb 22, 2018: Kadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHD
Feb 12, 2018: Kadmon Announces Positive Top line Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis
Feb 12, 2018: Kadmon to Host Webcast and Conference Call to Discuss Topline Results of KD025 in IPF
Dec 10, 2017: Kadmon Presents Updated Positive Phase 2 Data on KD025 in cGVHD at ASH Annual Meeting
Nov 01, 2017: Kadmon to Present New Data from Ongoing Phase 2 Study of KD025 in cGVHD at ASH Annual Meeting
Oct 06, 2017: FDA Grants Orphan Drug Designation to Kadmon’s KD025 for the Treatment of cGVHD
Aug 11, 2017: Kadmon to Present Preclinical Data on ROCK Inhibition in Pulmonary Fibrosis at IPF Summit 2017
Aug 02, 2017: BioAxone BioSciences Receives Notice of Award for NIH/SBIR Funding of IND-Enabling Studies to Continue Development of BA-1049 to Treat Cerebral Cavernous Malformations
Jul 25, 2017: Kadmon Announces Supplemental Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
Jul 11, 2017: Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by Angion Biomedica Corp, H2 2018
Pipeline by Astex Pharmaceuticals Inc, H2 2018
Pipeline by BioAxone BioSciences Inc, H2 2018
Pipeline by HitGen LTD, H2 2018
Pipeline by Kadmon Corp LLC, H2 2018
Pipeline by Redx Pharma Plc, H2 2018
Pipeline by Vertex Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by Angion Biomedica Corp, H2 2018
Pipeline by Astex Pharmaceuticals Inc, H2 2018
Pipeline by BioAxone BioSciences Inc, H2 2018
Pipeline by HitGen LTD, H2 2018
Pipeline by Kadmon Corp LLC, H2 2018
Pipeline by Redx Pharma Plc, H2 2018
Pipeline by Vertex Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AbbVie Inc
Angion Biomedica Corp
Astex Pharmaceuticals Inc
BioAxone BioSciences Inc
HitGen LTD
Kadmon Corp LLC
Redx Pharma Plc
Vertex Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AbbVie Inc
Angion Biomedica Corp
Astex Pharmaceuticals Inc
BioAxone BioSciences Inc
HitGen LTD
Kadmon Corp LLC
Redx Pharma Plc
Vertex Pharmaceuticals Inc
